These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1751375)

  • 61. [Thrombotic microangiopathies: HUS/TTP. Physiopathological aspects].
    Sánchez Avalos JC
    Medicina (B Aires); 2000; 60(1):46-58. PubMed ID: 10835700
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
    Furlan M; Robles R; Morselli B; Sandoz P; Lämmle B
    Thromb Haemost; 1999 Jan; 81(1):8-13. PubMed ID: 10348715
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
    George JN
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):627-32. PubMed ID: 16167049
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Thrombotic thrombocytopenic purpura attributable to von Willebrand factor-cleaving protease inhibitor in an 8-year-old boy.
    Robson WL; Tsai HM
    Pediatrics; 2002 Feb; 109(2):322-5. PubMed ID: 11826215
    [No Abstract]   [Full Text] [Related]  

  • 65. [Thrombotic thrombocytopenic purpura in children -- pathophysiologic mechanisms and their clinical significance].
    Korczowski B
    Med Wieku Rozwoj; 2005; 9(4):753-61. PubMed ID: 16733283
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: pathophysiology and management.
    Myers L
    Nephrol Nurs J; 2002 Apr; 29(2):171-80; quiz 181-2. PubMed ID: 11997952
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of platelet inhibitors on the platelet aggregation induced by plasma from patients with thrombotic thrombocytopenic purpura.
    Lian EC; Savaraj N
    Blood; 1981 Aug; 58(2):354-9. PubMed ID: 6264998
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles.
    Kelton JG; Warkentin TE; Hayward CP; Murphy WG; Moore JC
    Blood; 1992 Nov; 80(9):2246-51. PubMed ID: 1421394
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Proteolytic degradation of high molecular weight kininogen in acute thrombotic thrombocytopenic purpura.
    Pavord S; Kelton JG; Warner MN; Moore JC; Warkentin TE; Hayward CP
    Br J Haematol; 1997 Jun; 97(4):762-7. PubMed ID: 9217174
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Intravascular platelet activation in the hemolytic uremic syndrome.
    Walters MD; Levin M; Smith C; Nokes TJ; Hardisty RM; Dillon MJ; Barratt TM
    Kidney Int; 1988 Jan; 33(1):107-15. PubMed ID: 3280851
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Plasma from a patient with thrombotic thrombocytopenic purpura induces endothelial cell apoptosis and platelet aggregation.
    Wu XW; Li QZ; Lian EC
    Thromb Res; 1999 Jan; 93(2):79-87. PubMed ID: 9950261
    [No Abstract]   [Full Text] [Related]  

  • 72. Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties.
    Grignani G; Falanga A; Pacchiarini L; Alessio MG; Zucchella M; Fratino P; Donati MB
    Int J Cancer; 1988 Oct; 42(4):554-7. PubMed ID: 3170028
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Decrease in vivo of cysteine endopeptidases in blood of patients with tumor of the larynx.
    Mikulewicz W; Berdowska I; Jarmułowicz J; Siewiński M
    Anticancer Drugs; 1993 Jun; 4(3):341-4. PubMed ID: 8358062
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid.
    Cooling LL; Walker KE; Gille T; Koerner TA
    Infect Immun; 1998 Sep; 66(9):4355-66. PubMed ID: 9712788
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Further characterization of platelet-aggregating cysteine proteinase activity in thrombotic thrombocytopenic purpura.
    Consonni R; Falanga A; Barbui T
    Br J Haematol; 1994 Jun; 87(2):321-4. PubMed ID: 7947274
    [TBL] [Abstract][Full Text] [Related]  

  • 76. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
    Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
    N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
    Moake JL; McPherson PD
    Am J Med; 1989 Sep; 87(3N):9N-15N. PubMed ID: 2486537
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
    Furlan M; Lämmle B
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A cathepsin-like cysteine proteinase proaggregating activity in thrombotic thrombocytopenic purpura.
    Falanga A; Consonni R; Ruggenenti P; Barbui T
    Br J Haematol; 1991 Nov; 79(3):474-80. PubMed ID: 1751375
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.